Rivaroxaban for Secondary Prophylaxis of Atherothrombosis Complications in Patients With Recent Acute Coronary Syndrome

повторные атеротромботические события, острый коронарный синдром, профилактика, secondary of atherothrombosis complications, acute coronary syndrome, prophylaxis

1. Ardissino D., Merlini P. A., Bauer K. A., Galvani M., Ottani F., Franchi F., Bertocchi F., Rosenberg R. D., Mannucci P. M. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003;102 (8):2731-2735.

2. Testa L., Zoccai G. B., Porto I. et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J. Cardiol 2007;99 (12):1637-642.

3. Wallentin L., Wilcox R. G., Weaver W. D., Emanuelsson H., Goodvin A., Nyström P., Bylock A. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362 (9386):789-797.

4. Oldgren J., Budaj A., Granger C. B. et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32 (22):2781-2789.

5. APPRAISE Steering Committee and Investigators, Alexander J. H., Becker R. C., Bhatt D. L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention ofAcute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119 (22):2877-2885.

6. Alexander J. H., Lopes R. D., James S. et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl J. Med 2011;365 (8):699-708.

7. Mega J. L., Braunwald E., Mohanavelu S. et al.; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374 (9683):29-38.

8. Mega J. L., Braunwald E., Wiviott S. D. et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl J. Med 2012;366 (1):9-19.

9. Mega J. L., Braunwald E., Wiviott S. D. et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J. Cardiol 2013;112 (4):472-478.

10. Mega J. Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trial. P5518, ESC CONGRESS 2014.; European Medicines Agency. Xarelto assessment report. London 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Assessment_Report_-_Variation/hum an/000944/WC500144718.pdf (Accessed 23 June 2014). L. RU. GM.05.2015.0603

11. Brazhnik V.A., Zateishchikov D. A. Obostrenie ishemicheskoi bolezni serdtsa: b alans riska bolezni i riska lecheniya. Consilium Medicum 2015;1

12. Khirmanov V. N. Novye antikoagulyanty v lechenii bol'nykh, nedavno perenesshikh ostryi koronarnyi sindrom. Mesto riaroksabana. Kardiologiya 2015;6:72-81

13. Rossiiskie rekomendatsii ministerstva zdravookhraneniya «Diagnostika i lechenie bol'nykh ostrym IM s pod"emom segmenta ST elektrokardiogrammy». Kardiologicheskii vestnik 2014;4:90-60

14. Rossiiskie klinicheskie rekomendatsii «Ostryi infarkt miokarda s pod"emom segmenta ST kardiogrammy: reabilitatsiya i vtorichnaya profilaktika», CardioSomatika, Prilozhenie № 1, M., 2014;1:5-40.

15. Steg P. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33 (20):2569-2619.

16. Roffi M. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehv320.

17. Pandor A. et al. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2016;34 (5):463-477.

18. Shatalova O. V., Moiseev S. V. Kliniko-ekonomicheskii analiz primeneniya rivaroksabana posle ostrogo infarkta miokarda. Klin farmakol ter 2015;24 (1):83-87

19. Mak K.-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012;2: e001592. https://doi.org/10.1136/bmjopen-2012-001592.